Journal Home
Search for

Volume 93, Issue 8, Pages 2734-2737 (15 May 2010)


View previous. 41 of 52 View next.

Early demonstration of postoperative adhesions in a rodent model

Frank D. Yelian, M.D., Ph.D., Valerie I. Shavell, M.D., Michael P. Diamond, M.D.Corresponding Author Informationemail address

Received 12 November 2009; received in revised form 13 January 2010; accepted 20 January 2010. published online 16 March 2010.

Objective

To assess the cellular and molecular mechanisms of postoperative adhesion development in a rodent model.

Design

Prospective randomized controlled study.

Setting

Research laboratory.

Patients

Thirty sexually mature female Sprague-Dawley rats.

Interventions

Cecal abrasion.

Main outcome measure(s)

At 0, 2, 4, 8, 16, 24, 48, 72, 96, 168, 336, and 504 hours after cecal abrasion, one to three rats were sacrificed (n = 26). Four nonabraded rats served as controls. Peritoneal adhesion status was evaluated and tissue was collected for histologic and immunohistochemical investigation.

Results

Postoperative tissue attachments were identified as early as 2 hours after cecal abrasion. Significant local edema and vessel congestion appeared within 2 hours, and cellular proliferation was observed at 24 hours; angiogenesis and tissue proliferation remained present at 2 weeks. β1 integrin was highly expressed early and was thereafter decreased. Cellular fibronectin was not detectable until 1 week after cecal abrasion.

Conclusions

Postoperative adhesions are initiated as rapidly as 2 hours after surgical intervention in this rodent model.

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan

Corresponding Author InformationReprint requests: Michael P. Diamond, M.D., Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, 3800 Woodward Avenue, Suite 320-D, Detroit, MI 48201 (TEL: 313-993-4523; FAX: 313-993-4534).

 F.D.Y. has nothing to disclose. V.I.S. has nothing to disclose. M.P.D. has performed contract research for Neurocrine, Boehringer Ingelheim, Busante, Ethicon, and Wyeth; been a consultant for Genzyme, Omrix, Neomend, ARC, Baxter and Serono; and member of the board of directors for ARC.

PII: S0015-0282(10)00129-9

doi:10.1016/j.fertnstert.2010.01.054


View previous. 41 of 52 View next.